Figures & data
Table 1 Characteristics of Oral and Injectable DMA Users with MS and the Standard Differences of Covariates Between Both Groups Before and After IPTW Weighting: IBM MarketScan 2010–2012
Figure 2 Adherence Trajectories of Patients with MS who received Oral Fingolimod or Injectable DMAs. Rapid discontinuers: Patients who discontinued DMAs early within 3–4 months after the initiation. Complete adherers: Patients who were almost completely adherent to DMA throughout the follow-up period. Slow decliners: Patients whose adherence gradually declined during the follow-up period.
![Figure 2 Adherence Trajectories of Patients with MS who received Oral Fingolimod or Injectable DMAs. Rapid discontinuers: Patients who discontinued DMAs early within 3–4 months after the initiation. Complete adherers: Patients who were almost completely adherent to DMA throughout the follow-up period. Slow decliners: Patients whose adherence gradually declined during the follow-up period.](/cms/asset/333f20c0-c7be-434a-b093-71d83b458d84/dppa_a_12178578_f0002_c.jpg)
Table 2 Adherence Trajectories Between Oral Fingolimod and Injectable DMA Users in Patients with MS
Table 3 Findings of IPTW Weighted Multinomial Logistic Regression